Pedram Hamrah, MD
Ophthalmology · Tampa, FLNPI 1366483778
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $168,849 of the $186,913 with a category attached, or 90.3%. 23 manufacturers reported payments, led by Dompe US, Inc. at 51.5% of the total. Reporting peaked in 2023 at $56,426 and has fallen 66.3% since, to $19,021 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 184 payments — averaging $1015.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dompe US, Inc.$96K
- Sanofi-aventis U.S. LLC$14K
- Kala Pharmaceuticals, Inc.$14K
- Amgen$13K
- Sanofi US Services Inc.$13K
- Dompe Farmaceutici S.p.a.$10K
- plus $27K from 17 others
Across 77 payments — averaging $26,709 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dompe US, Inc.$919K
- Dompe Farmaceutici S.p.a.$770K
- Novartis$207K
- Ocular Therapeutix, Inc.$112K
- Bausch Health US, LLC$23K
- E.r. Squibb & Sons, L.L.C.$19K
- plus $7K from 2 others
What the payments were for
- Consulting fees$168,84990%
- Speaking & faculty fees$9,1945%
- Travel & lodging$4,4282%
- Food & beverage$4,3232%
- Education$1200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dompe US, Inc. | 44 | $96,237 |
| Sanofi-aventis U.S. LLC | 21 | $13,878 |
| Kala Pharmaceuticals, Inc. | 20 | $13,559 |
| Amgen(2 entities) | 15 | $13,230 |
| Sanofi US Services Inc. | 2 | $12,650 |
| Dompe Farmaceutici S.p.a. | 2 | $10,000 |
| Alcon Research LLC | 2 | $7,500 |
| Axogen | 7 | $6,850 |
| Biotissue Holdings Inc. | 10 | $3,724 |
| Tarsus Pharmaceuticals, Inc. | 12 | $2,120 |
| Alcon | 4 | $1,611 |
| Aerie Pharmaceuticals, Inc. | 1 | $1,600 |
| Eyevance Pharmaceuticals LLC | 4 | $1,365 |
| Biogen | 1 | $648 |
| Bausch & Lomb Americas Inc. | 12 | $397 |
| Novartis | 3 | $395 |
| Thea Pharma Inc. | 10 | $368 |
| Shire North American Group Inc | 2 | $267 |
| Ocular Therapeutix, Inc. | 4 | $149 |
| Oyster Point Pharma, Inc. | 2 | $140 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $135 |
| Sun Pharmaceutical Industries Inc. | 2 | $77 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oxervate$13,016
- TEPEZZA$12,963
- Prokera$3,575
- AmnioGraft$3,575
- AmnioGuard$3,575
- AVANCE NERVE GRAFT$2,915
- AxoGuard Nerve Connector$2,915
- AxoGuard Nerve Protector$2,915
- AXOGUARD HA+ NERVE PROTECTOR$2,915
- AxoGuard Nerve Cap$2,915
- INVELTYS$2,443
- EYSUVIS$2,250
- Rocklatan$1,600
- TRYPTYR$1,500
- Flarex$1,250
- XIIDRA$410
- MIEBO$144
- TYRVAYA$108
How this compares
$186,913 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 76 | $2,438,779 |
| MieboPerfluorohexyloctane/Pf | 178 | $218,975 |
| RestasisCyclosporine | 186 | $210,917 |
| Loteprednol Etabonate | 393 | $73,734 |
| Cyclosporine | 94 | $44,953 |
| XiidraLifitegrast | 42 | $28,502 |
| LotemaxLoteprednol Etabonate | 58 | $19,557 |
| TyrvayaVarenicline Tartrate | 24 | $17,626 |
| VevyeCyclosporine | 17 | $17,450 |
| CequaCyclosporine | 15 | $9,882 |
| AzasiteAzithromycin | 16 | $9,545 |
| Lotemax SmLoteprednol Etabonate | 35 | $9,280 |
| RhopressaNetarsudil Mesylate | 19 | $9,039 |
| AlrexLoteprednol Etabonate | 14 | $4,789 |
| Prednisolone Acetate | 90 | $4,093 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $96,237 | $2,438,77976 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $397 | $247,477220 claims |
| AbbVieRestasis | $12 | $210,917186 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax, Lotemax Sm, Alrex | $135 | $107,359500 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $140 | $17,62624 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $77 | $9,88215 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $1,600 | $9,03919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Tampa
- Courtney BoveeTampa$796K
- Ivan SunerTampa$378K
- Thomas NewsomTampa$186K
- Don PerezTampa$178K
- Brian SzaboTampa$86K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.